Osteosarcoma, Chondrosarcoma
Conditions
Keywords
Osteosarcoma, Chondrosarcoma, Tumor associated neutrophils
Brief summary
Hypothesis: Tumor infiltrating neutrophils are present in osteosarcomas and chondrosarcomas and Experimental design: Exploratory observational research Population: Adult patients with osteosarcoma or chondrosarcoma Assessment criteria: Determination of the presence of TANs within tumors and their N1 or N2 profile, the presence of other immune cells, and the PDL-1 status of the tumor. Investigation plan: Proposal to participate at all eligible patient during the preoperative consultation. If the patient agrees to participate in the study he/she will be included. Participation in the study will not affect its coverage. Patient participation will lead to: * Taking samples from an operative part, * The collection of demographic data (age, sex, height, weight, body mass index), family history of cancer, history of bone trauma, sports practice, clinical and anatomopathology reports and data, medical history (Diabetes, Cardiovascular Diseases, Infectious Diseases, Autoimmune Diseases, Bone Metabolism Disorders, Allergies, Menopause, Drug treatments followed, Psychiatric disorders). Statistical analysis plan: Description in frequency of the presence of TANs, of N1 and N2 profiles, of the presence of other immune cells both qualitatively and quantitatively. Analysis in subgroups on relevant criteria (age, sex, location, type of tumor).
Interventions
No intervention
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient of 18 years and more * Patient of the Orthopedic and Traumatological Surgery Department of the Reims University Hospital or the Godinot Institute * Patient with osteosarcoma or chondrosarcoma to be operated on regardless of stage. * Patient agreeing to participate in the study (informed consent form) * Patient fluent in French * Patient affiliated with a social security regimen
Exclusion criteria
* Patient having a medical history that may compromise the protocol (psychiatric, medical or pharmacological disorders such as the use of anti-inflammatory drugs, or any compound that may alter or modify the inflammatory reaction in the week preceding the protocol). * Pregnant or breastfeeding women * Patient with eating disorders (anorexia, bulimia, overeating) * Patient protected by law (guardianship, curatorship, hospitalized without their consent and not protected by law, deprived of liberty)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the presence of neutrophils in sarcoma-affected tissues | Time of surgery | Flow cytometry analysis on excised tissues |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of flow cytometry and histology for neutrophil assessment in sarcoma-affected tissues | Time of surgery | Neutrophil identification thanks to CD66b marker with both the techniques |
| Identification of neutrophils N1 or N2 profile in sarcoma-affected tissues | Time of surgery | Flow cytometry (CD45 CD66b CD182 CD184 CD195) |
| Identification of non-neutrophil leukocytes in sarcoma-affected tissues | Time of surgery | Flow cytometry analysis (CD45 CD3 CD4 CD8 CD19 CD33 CD80 CD163) |
| Determination of PDL1 status of neutrophils in sarcoma-affected tissues | Time of surgery | Flow cytometry analysis (CD45 CD66b CD 274) |
Countries
France